AstraZeneca's stock experienced a notable decline of 6.5% in early trading after the Financial Times reported that the company has been in discussions with Bristol Myers Squibb regarding a potential merger that could be valued at approximately $400 billion. This deal, if finalized, would rank among the largest mergers in history.
The news has had a ripple effect, contributing to a flat performance of the FTSE 100 index, which includes AstraZeneca. Both companies have not provided comments on the situation, with AstraZeneca declining to respond and Bristol Myers Squibb not available for comment outside of normal hours.
The market's reaction underscores the uncertainty and potential risks associated with such a massive consolidation in the pharmaceutical industry